STADA

Overview

Overview

STADA is a publicly traded, international
company with a focus on the healthcare market.

STADA Business Model

  • Focus on products with off-patent active pharmaceutical ingredients in the health care and, in particular, in the pharmaceutical market
  • Core segments
    • Generics (59% of Group sales)
    • Branded Products (39% of Group sales)




 

  • Strategic success factors
    • Orientation on long-term growth markets
    • Comprehensive generics portfolio and numerous attractive-margin branded products
    • Strong product development without cost-intensive research
    • International sales structure
    • Active acquisition policy, particularly in the area of branded products, including experienced integration management
    • Functionally organized Group with short decision-making channels and close to market sales companies
    • Culture of continuous cost optimization including efficient cost management

STADA Financial Year 2014

  • Group sales rise by 3% to € 2.06 billion – Group sales adjusted for currency and portfolio effects records slight growth of 1%
  • Reported key earnings figures
    • Reported EBITDA increases by 9% to € 418.8 million
    • Reported net income decreases significantly by 47% to € 64.6 million
    • Earnings per share records a substantial decrease of 48% to € 1.07
  • All adjusted key earnings figures
    • Adjusted EBITDA records growth by 4% to € 431.9 million
    • Adjusted net income rises substantially by 16% to € 186.2 million
    • Adjusted earnings per share increases clearly by 14% to € 3.08
  • Pleasing development in Central Europe with a sales increase of 11% and in Asia & Pacific with sales growth of 52%
  • Further expansion of the self-pay patient portfolio from high sales growth of 14% in branded products – share of branded products in adjusted operating profit of core segments rises to 52%
  • Introduction of a centralized portfolio management structure including a decentralized marketing
  • Successful product development with 626 product launches worldwide
  • Further acquisitions to strengthen the Branded Products segment
  • Successful securing of promissory notes in the amount of € 270 million
  • Dividend proposal of € 0.66 per STADA common share unchanged to the previous year


STADA Outlook

  • Outlook for 2015
    • Slight growth in Group sales adjusted for currency and portfolio effects
    • Substantial decrease in adjusted EBITDA and adjusted net income
    • Ratio of net debt, excluding further acquisitions, to adjusted EBITDA at a level of nearly 3


 

Quality at STADA

Quality at STADA

Quality and responsibility to all who use our products or services is a fundamental part of our corporate strategy.

Learn more

Career at STADA

Career at STADA

STADA's employees, with their extensive expertise, their experience and their strong commitment, play an important part in the longstanding success of the Group.

Learn more

Media Relations

Media Relations

In addition to press releases on current issues Journalists can find background information on areas such as personnel, organizational structure, products and manufacturing.

Learn more

Career at STADA

Career at STADA

STADA's employees, with their extensive expertise, their experience and their strong commitment, play an important part in the longstanding success of the Group.

Learn more

entdecken